Korro Bio, Inc. (KRRO)
| Market Cap | 154.61M +11.2% |
| Revenue (ttm) | 3.84M -20.3% |
| Net Income | -113.50M |
| EPS | -11.41 |
| Shares Out | 14.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,667 |
| Open | 11.09 |
| Previous Close | 11.18 |
| Day's Range | 10.46 - 11.28 |
| 52-Week Range | 5.20 - 55.89 |
| Beta | 2.10 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+86.57%) |
| Earnings Date | May 7, 2026 |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe d... [Read more]
Financial Performance
In 2025, Korro Bio's revenue was $6.39 million, an increase of 181.46% compared to the previous year's $2.27 million. Losses were -$117.26 million, 40.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 86.57% from the latest price.
News
Korro Bio initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Korro Bio (KRRO) with an Outperform rating and $21 price target
Korro Bio selects KRRO-111 as development candidate
Korro Bio (KRRO) announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development. KRRO-111 is a proprietary GalNAc-conjugated oligonucleot...
Korro Bio price target lowered to $15 from $20 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Korro Bio (KRRO) to $15 from $20 and keeps a Buy rating on the shares. The firm cites the…
Korro Bio initiated with a Buy at Citi
Citi initiated coverage of Korro Bio (KRRO) with a Buy rating and $21 price target While the shares sold off 60% on the “modest” Phase 1/2 REWRITE data, the readout…
Korro Bio upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target
JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
As previously reported, JonesResearch analyst Catherine Novack upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target after the company reported Q1 results. While both Korro’s GalNAc-conju...
Korro Bio reports Q1 EPS ($1.69), consensus ($1.98)
“The first quarter marked significant scientific progress for Korro as we continued to advance our OPERA platform and build a pipeline of differentiated RNA editing medicines,” commented Ram Aiyar, Ch...
Korro Bio Quarterly report: Q1 2026
Korro Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
Korro Bio Earnings release: Q1 2026
Korro Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Korro Bio Slides: Corporate presentation
Korro Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Korro Bio Proxy statement: Proxy filing
Korro Bio filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Korro Bio Proxy statement: Proxy filing
Korro Bio filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Korro Bio Slides: Corporate presentation
Korro Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
Korro Bio files to sell 7.65M shares of common stock for holders
17:06 EDT Korro Bio (KRRO) files to sell 7.65M shares of common stock for holders
Korro Bio Registration statement: Registration Filing
Korro Bio filed a registration statement on March 13, 2026, providing details about a securities offering with the SEC.
Korro Bio price target raised to $22 from $21 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Korro Bio (KRRO) to $22 from $21 and keeps an Overweight rating on the shares. The firm updated its model after Korro…
Korro Bio upgraded to Outperform from Market Perform at Raymond James
Raymond James upgraded Korro Bio (KRRO) to Outperform from Market Perform with a $23 price target The firm sees an improved outlook given the company’s pivot into hyperammonemia indications urea…
Korro Bio Earnings release: Q4 2025
Korro Bio released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Korro Bio Annual report: Q4 2025
Korro Bio has published its Q4 2025 annual report on March 12, 2026.
Korro Bio prices 4.5M shares at $11.11 in private placement
Korro Bio (KRRO) entered into a subscription agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $85 million to the…
Korro Bio upgraded to Buy from Hold at Clear Street
Clear Street upgraded Korro Bio (KRRO) to Buy from Hold with a price target of $18, up from $10. The firm believes new lead program, KRRO-121 for hyperammonemia, clearly addresses…
Korro Bio upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Korro Bio (KRRO) to Outperform from Market Perform. The firm views the risk/reward as favorable for the OPERA Platform and KRRO-121, notes the analyst, who estimates a…
Korro Bio management to meet virtually with Cantor Fitzgerald
Virtual Meeting to be held on February 4 hosted by Cantor Fitzgerald.
Korro Bio upgraded to Buy from Neutral at Chardan
Chardan upgraded Korro Bio (KRRO) to Buy from Neutral with a $15 price target following the analyst day. The company says the company has “turned the page.” It cites the…
Piper upgrades Korro to Overweight on bullish KRRO-121 view
Piper Sandler analyst Yasmeen Rahimi last night upgraded Korro Bio (KRRO) to Overweight from Neutral with a price target of $30, up from $11, following the analyst day. Piper left…